Literature DB >> 14679113

Indolent lymphoma: the pathologist's viewpoint.

S A Pileri1, P L Zinzani, P Went, A Pileri, M Bendandi.   

Abstract

Indolent lymphomas have recently been the object of numerous studies, which have focused on new aspects relevant both for the better comprehension of their histogenesis and the identification of new therapeutic strategies. As marginal-zone lymphoma (MZL) represents the category of indolent lymphomas that has obtained more benefit from such an approach, the authors focused on the most recent achievements and not yet solved controversies in this area. In spite of their postulated common derivation, the three categories of MZL of the WHO Classification appear dissimilar. In fact, they show significant molecular differences among them as well as a certain heterogeneity within each group. By no means, there is a cogent need of more refined tools to revise these neoplasms and to produce a more rational grouping. The recent identification of the IRTA gene family corresponding to IG-like receptors differentially expressed in B-cells might contribute to their better understanding.

Entities:  

Mesh:

Year:  2004        PMID: 14679113     DOI: 10.1093/annonc/mdh002

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


  5 in total

Review 1.  The paradox of response and survival in cancer therapeutics.

Authors:  Carol Ann Huff; William Matsui; B Douglas Smith; Richard J Jones
Journal:  Blood       Date:  2005-09-08       Impact factor: 22.113

2.  Surgery and chemotherapy versus chemotherapy as treatment of high-grade MALT gastric lymphoma.

Authors:  Agustín Avilés; Natividad Neri; M Jesús Nambo; Judith Huerta-Guzman; Sergio Cleto
Journal:  Med Oncol       Date:  2006       Impact factor: 3.064

3.  An uncommon clinical presentation of retroperitoneal non-Hodgkin lymphoma successfully treated with chemotherapy: a case report.

Authors:  Chiara Fulignati; Pietro Pantaleo; Greta Cipriani; Marianna Turrini; Rosalia Nicastro; Roberto Mazzanti; Bruno Neri
Journal:  World J Gastroenterol       Date:  2005-05-28       Impact factor: 5.742

4.  Mucosa-associated lymphoid tissue (MALT) lymphoma of the stomach: results of a controlled clinical trial.

Authors:  Agustin Avilés; María Jesús Nambo; Natividad Neri; Alejandra Talavera; Sergio Cleto
Journal:  Med Oncol       Date:  2005       Impact factor: 3.064

5.  Efficacy and Safety of ABP 798: Results from the JASMINE Trial in Patients with Follicular Lymphoma in Comparison with Rituximab Reference Product.

Authors:  Dietger Niederwieser; Caroline Hamm; Patrick Cobb; Mindy Mo; Cecily Forsyth; Alessandra Tucci; Vladimir Hanes; Vincent Delwail; Roman Hajek; David Chien
Journal:  Target Oncol       Date:  2020-10       Impact factor: 4.493

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.